摘要
目的 分析替加环素联合头孢哌酮舒巴坦对多重耐药鲍曼不动杆菌肺部感染的临床疗效。方法 回顾性分析我院于2013年1月-2014年12月收治的114例多重耐药鲍曼不动杆菌肺部感染患者的病历资料,根据治疗方法的不同将其分为头孢哌酮舒巴坦治疗组（对照组,n=62）和替加环素联合头孢哌酮舒巴坦治疗组（观察组,n=52）。比较两组患者的治疗效果。结果 两组患者治疗后白细胞（WBC）、C反应蛋白（CRP）及降钙素原（PCT）较治疗前均显著下降（P〈0.05）;观察组治疗后CRP和PCT均显著低于对照组（P〈0.05）,WBC差异无统计学意义（P〉0.05）。观察组治疗有效率为86.54%,显著高于对照组的67.74%（P〈0.05）。结论 对多重耐药鲍曼不动杆菌肺部感染的联合用药治疗效果优于单药治疗。
Objective To analyze clinical effect of tigecycline plus cefoperazone sulbactam for treatment of pulmonary infection due to multidrug-resistant Acinetobacter Bauman （MRADB）. Methods 114 cases of pulmonary infected pa- tients with MRADB,who were admitted to our hospital from January 2013 to December 2015,were analyzed retrospectively.The patients were divided into 2 groups： the control group （62 cases） was received Cefoperazone Sulbactam,ohser- vation group （52 cases） was received Tigecyeline plus Cefoperazone Sulbactam.The clinical effects of the 2 groups were compared. Results CRP,PCT,WBC after treatment were significantly lower than before in two groups （P〈0.05）;CRP and PCT after treatment of observation group were significantly lower than those in control group （P〈0.05）,no significant dif- ference in WBC （P〉0.05）.The total effective rate of observation group was significantly higher than that of control group （86.54% vs 67.74%）. Conclusion The clinical effect of combination therapy for pulmonary infection due to MDRAB may be superior to monotherapy.
出处
《中国当代医药》
2016年第13期145-147,共3页
China Modern Medicine
关键词
替加环素
头孢哌酮舒巴坦
多重耐药鲍曼不动杆菌
肺部感染
Tigecycline
Cefoperazone Sulbactam
Muhidrug-resistant Acinetobacter baumannii
Pulmonary infection
